Aptinyx — Investor Presentation (August 2020)
43 slides from Aptinyx's investor presentation, Aug 5, 2020
Slide 1: Innovative Therapies for Disorders of the Brain and Nervous System
Innovative Therapies for Disorders of the Brain and Nervous System Corporate Presentation August 2020 Nasdaq: APTX
Slide 2: Forward-looking statements
Forward-looking statements This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any sec
Slide 3: Aptinyx: Who we are
Aptinyx: Who we are OUR MISSION is to discover and develop innovative therapies for challenging disorders of the brain and nervous system OUR PLATFORM has yielded novel product candidates that modulate NMDA receptors, which are vital to normal brain physiology, and help restore normal balance in the
Slide 4: Advancing a leading pipeline of CNS therapies
Advancing a leading pipeline of CNS therapies INDICATION CHRONIC PAIN FRANCHISE PRECLINICAL/ IND ENABLINGPHASE 1PHASE 2PHASE 3 REGISTRATION/ COMMERCIAL NYX-2925 Fibromyalgia Painful Diabetic Peripheral Neuropathy Phase 2b Phase 2b Anticipate recommencing study September 2020 Anticipate recommencing
Slide 5: Experienced management team and a board of highly regarded healthcare investors and leaders
Experienced management team and a board of highly regarded healthcare investors and leaders EXECUTIVE MANAGEMENT TEAMBOARD OF DIRECTORS Norbert Riedel, PhD President & CEO Patrick Enright (Chairman) Founder & Managing Director Patty Adams SVP – Human Resources & Administration Rolando Gutierrez-Este
Slide 6: NMDA receptor modulation: An elegant approach to restoring normal balance in the CNS
NMDA receptor modulation: An elegant approach to restoring normal balance in the CNS APTINYX NOVEL MODULATION NORMAL BALANCE AGONIST ONEXCITOTOXICITY OVER-ACTIVATION DISSOCIATION OFFPSYCHOTOMIMETIC ABUSE LIABILITY ANTAGONISTINHIBITION SYNAPSEPOSTSYNAPTIC NEURON CURRENT THERAPEUTIC APPROACHES Aptinyx
Slide 7: Modulation: a differentiated approach to targeting NMDA receptors
Modulation: a differentiated approach to targeting NMDA receptors Intracellular Calcium Measured in Rat Cortical Neurons Modulation – NYX-2925 Antagonism – Ketamine Max enhancement ~20% VS Max inhibition ~20% Unlike full inhibition observed with ketamine, Aptinyx compounds demonstrate mild activatio
Slide 8: Modulation of NMDAr triggers a neurobiological cascade and enhances synaptic plasticity
Modulation of NMDAr with Aptinyx compounds triggers a neurobiological cascade and enhances synaptic plasticity—the foundation of neural cell communication Rapid receptor engagementLong-lasting effects on neural plasticity processes Learning Cognition Memory MoodSleep Molecules bind in novel, newly-c
Slide 9: NMDAr modulator discovery platform has produced > 1,000 unique compounds
NMDAr modulator discovery platform has produced > 1,000 unique compounds NMDA Receptor GluN1GluN2 Molecules bind at a novel, distinct, newly characterized binding domain Molecules demonstrate high oral bioavailability and stability Ifenprodil (2B) Zn2+ (2A>>2B) PYD-106 (2C) Molecules have diverse po
Slide 10: NMDA receptors are key targets for many CNS disorders
NMDA receptors are key targets for many CNS disorders CHRONIC PAIN ALZHEIMER’S DISEASE BIPOLAR DISORDER SCHIZOPHRENIA ANTI-NMDAR ENCEPHALITIS PTSD DEPRESSION CEREBRAL ISCHEMIA COGNITIVE IMPAIRMENT SUBSTANCE ABUSE AUTISM SPECTRUM DISORDERS TRAUMATIC BRAIN INJURY HUNTINGTON’S DISEASE Current areas of
Slide 11: Chronic Pain Franchise: NYX-2925 for Painful DPN & Fibromyalgia
Chronic Pain Franchise: NYX-2925 for Painful Diabetic Peripheral Neuropathy (DPN) & Fibromyalgia 11August 5, 2020
Slide 12: Favorable tolerability and dose-proportional PK of NYX-2925 observed in Phase 1 study
Favorable tolerability and dose-proportional PK of NYX-2925 observed in 84-subject Phase 1 study SINGLE ASCENDING DOSE PLASMA PKMULTIPLE ASCENDING DOSE PLASMA PKCSF CONCENTRATION Doses tested in Phase 2 Effective dose range preclinically NYX-2925 EXHIBITS FAVORABLE TOLERABILITY AND PK PROPERTIES: Dr
Slide 13: Chronic pain
CHRONIC PAIN Affects up to 100 MILLION people in the U.S. Current therapies have limited efficacy and substantial side effects Market leading therapies have significant drawbacks, yet have garnered >$5 BILLION in annual peak sales Current therapies have significant abuse liability 13August 5, 2020
Slide 14: Seeking to address centralized chronic pain conditions through novel NMDA receptor modulation
Seeking to address centralized chronic pain conditions through novel NMDA receptor modulation TIME PERIPHERAL PROCESSES e.g., inflammation, nerve injury CENTRAL PROCESSES e.g., plasticity, receptor changes, shifts in processing regions Central processing abnormalities are present in chronic pain con
Slide 15: Mechanism of NYX-2925 targets aberrant centralized pain processing
Mechanism of NYX 2925 targets aberrant centralized pain processing in chronic pain conditions NORMAL PAIN PROCESSING ABERRANT CENTRALIZED PAIN PROCESSING 1. Stimulus sensed by peripheral nerve 2. Impulses depolarize the dorsal horn, increasing Ca2+ in neurons, causing release of neurotransmitters 3.
Slide 16: Fibromyalgia is a centralized chronic pain condition that affects millions and is vastly underserved
Fibromyalgia is a centralized chronic pain condition that affects millions and is vastly underserved WHAT IS FIBROMYALGIA? 2 “rheumatic” disorder behind osteoarthritis A SUBSTANTIAL MARKET OPPORTUNITY WITH NO ADEQUATE THERAPEUTIC OPTIONS Aberrant processing in fibromyalgia — which can be objectively
Slide 17: Design of completed NYX-2925 neuroimaging biomarker study in fibromyalgia
Design of completed NYX-2925 Phase 2 neuroimaging biomarker study in patients with fibromyalgia N=22 MRIMRIMRI Screening Period MRIMRI* Follow-up Day -30 Day 1 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 DAILY PAIN SCORE *MRI at follow-up visit was optional Design optimized for within-patient i
Slide 18: Neuroimaging study results: significant effects on validated biomarkers of pain processing
Phase 2 neuroimaging study results: NYX-2925 demonstrated significant effects on primary endpoint, validated biomarkers of pain processing FMRI FINDINGS GLX/1H-MRS* FINDINGS Hyper-connectivity between brain regions is observed in fibromyalgia patients NYX-2925 significantly reduced levels of connect
Slide 19: Neuroimaging study results: improvements in patient-reported fibromyalgia symptoms
Phase 2 neuroimaging study results: NYX-2925 demonstrated meaningful improvements in patient-reported symptoms of fibromyalgia PAIN ENDPOINTSKEY QOL/FUNCTION ENDPOINTS Average Daily PainWorst Daily Pain Total FIQR Score*PROMISFM Total Fatigue Profile Score** Average Daily Pain: 19% improvement Worst
Slide 20: Completed first-in-patient Phase 2 study of NYX-2925 in painful DPN
Completed first-in-patient Phase 2 study of NYX-2925 in patients with painful DPN N=300 x SCREENING (2-4 WEEKS)BASELINE (1 WEEK) TREATMENT (4 WEEKS) SAFETY FOLLOW-UP (1 WK) Inclusion/exclusion eligibility Analgesic washout* Randomization eligibility Baseline pain score PLACEBO q.d. (N = 72) NYX-2925
Slide 21: DPN top-line results: analgesic signal, greater separation without concomitant analgesics
Phase 2 DPN top-line results: NYX-2925 demonstrated analgesic signal, with greater separation in patients not on concomitant analgesics CHANGE IN AVERAGE DAILY PAIN (PRIMARY EFFICACY ENDPOINT) Total Efficacy Population (N=300) Efficacy Population Not on Concomitant Analgesic (N=148) 50 mg NYX-2925:
Slide 22: NYX-2925 demonstrated robust analgesic effects in more chronic patients
NYX-2925 demonstrated robust analgesic effects in more chronic patients Change in Avg. Daily Pain Total Efficacy Pop. (N=300) Change in Average Daily Pain (Baseline to Week 4) by DPN Duration Duration of DPN Diagnosis ≥ 1 yrs (N=275) Change in NRS (0-10) Pain Score from Baseline ≥ 2 yrs (N=204) ≥ 3
Slide 23: Significant effects in advanced DPN population with no plateau in four weeks
Significant and clinically meaningful effects observed in advanced DPN population—with no plateau in four weeks CHANGE IN AVERAGE DAILY PAIN (PRIMARY EFFICACY ENDPOINT) Advanced DPN Population (N=127)* Advanced DPN Pop. Not on Concomitant Analgesic (N=64)* 50 mg NYX-2925: 31% reduction in pain 1.2-p
Slide 24: Effect of NYX-2925 in advanced DPN patients consistent across endpoints
Effect of NYX-2925 in advanced DPN patients was consistent across endpoints in the study Change in Worst Daily Pain (NRS) Score from Baseline ADVANCED DPN POPULATION (N=127)* Change in Average Pain on Walking (NRS) Score from Baseline Change in Daily Sleep Interference (DSIS) Score from Baseline 50
Slide 25: Key study findings provide foundation for further development of NYX-2925 in painful DPN
Key study findings provide foundation for further development of NYX-2925 for painful DPN NYX-2925 was well tolerated in the study with no SAEs and an overall AE profile comparable to placebo Study results inform follow-up Phase 2b study of NYX-2925 in advanced DPN patients, currently ongoing Patien
Slide 26: Conducting two follow-up Phase 2b studies of NYX-2925 in centralized chronic pain conditions
Conducting two follow-up Phase 2b studies of NYX-2925 in centralized chronic pain conditions FIBROMYALGIA PAINFUL DPN ~300-patient, placebo-controlled, double-blind 12-week endpoint 50 mg or 100 mg daily vs placebo No concomitant analgesics ~200-patient, placebo-controlled, double-blind Advanced DPN
Slide 27: Development summary of NYX-2925 for painful DPN and fibromyalgia
Development summary of NYX-2925 for painful DPN and fibromyalgia xSTRONG PRECLINICAL EVIDENCE – robust, long-lasting effects seen across various models of neuropathic pain xCOMPLETED THREE PHASE 1 STUDIES – favorable tolerability, PK, and CNS exposure observed, as well as proof of activity and NMDA
Slide 28: Psychiatry Franchise: NYX-783 for PTSD
Psychiatry Franchise: NYX-783 for Post-Traumatic Stress Disorder (PTSD) 29August 5, 2020
Slide 29: PTSD
PTSD ~8.5 2 APPROVED THERAPIES both approved 10+ years ago MILLION people suffering from PTSD in the U.S. with an estimated lifetime prevalence of 6.8% 50-66 % also battle simultaneous addiction to alcohol and other drugs Numerous causes of PTSD Elevated suicide rates among PTSD sufferers ~20 vetera
Slide 30: NYX-783 in Phase 2 for the treatment of PTSD
NYX-783 in Phase 2 for the treatment of PTSD CLEAR MECHANISTIC RATIONALE STRONG PRECLINICAL EVIDENCE Learning and memory dysfunction is at the root of PTSD symptomatology D-cycloserine (DCS), an NMDAr partial agonist, has demonstrated effect in PTSD Robust and long-lasting activity observed in model
Slide 31: Preclinical work shows NYX-783 potential to address diverse symptomatology of PTSD
Preclinical work demonstrates that NYX-783 has the potential to address the diverse symptomatology of PTSD Fear Extinction Rapid, robust, and enduring effects in conditioned fear and extinction learning models in rats Mood Significantly improves negative mood/affect in Porsolt forced swim model PTSD
Slide 32: Favorable tolerability and dose-proportional PK of NYX-783 observed in Phase 1 study
Favorable tolerability and dose-proportional PK of NYX-783 observed in 70-subject Phase 1 study SINGLE ASCENDING DOSE PLASMA PKMULTIPLE ASCENDING DOSE PLASMA PKCSF CONCENTRATION NYX-783 50 mg PO NYX-783 EXHIBITS FAVORABLE TOLERABILITY AND PK PROPERTIES: Predictable and dose-proportional PK Cleared f
Slide 33: First-in-patient exploratory Phase 2 study of NYX-783 in PTSD
First-in-patient exploratory Phase 2 study of NYX-783 in PTSD An important first step in evaluating the efficacy of a novel mechanism PRECLINICAL PHASE 1 STUDY OBJECTIVE Inform future development with regard to: Patient inclusion/exclusion criteria PHASE 2 (FIRST-IN-PATIENT) Dose level PHASE 2 (VALI
Slide 34: Enrollment completed in ongoing exploratory Phase 2 study of NYX-783 in PTSD
Enrollment completed in ongoing exploratory Phase 2 study of NYX-783 in patients with PTSD SCREENING (2 – 4 WEEKS)STAGE 1 (4 WEEKS)STAGE 2 (4 WEEKS) Diagnosis of PTSD (DSM-5) CAPS-5 ≥ 30 PCL-5 ≥ 38 Placebo non-responder criteria: • CAPS-5 reduction from baseline ≤35% • CAPS-5 score at re-randomizati
Slide 35: Development summary of NYX-783 for PTSD
Development summary of NYX-783 for PTSDx STRONG PRECLINICAL EVIDENCE in fear extinction and other psychiatric models x FAVORABLE TOLERABILITY, PK, AND CNS EXPOSURE demonstrated in completed Phase 1 study in humans EXPLORATORY PHASE 2 STUDY ONGOING – Results expected by November 2020 will inform next
Slide 36: Neurology Franchise: NYX-458 for Parkinson's Cognitive Impairment
Neurology Franchise: NYX-458 for Parkinson’s Cognitive Impairment 37August 5, 2020
Slide 37: Cognitive impairment in Parkinson's disease
COGNITIVE IMPAIRMENT in PARKINSON’S DISEASE ~1 MILLION 1 people suffering from Parkinson’s disease in the U.S. ~500k ~250k with MCI ~250k with dementia THERAPY approved to date, Exelon®, which is minimally efficacious in PD patients 38August 5, 2020
Slide 38: NYX-458 in Phase 2 for cognitive impairment associated with Parkinson's disease
NYX-458 in Phase 2 for cognitive impairment associated with Parkinson’s disease CLEAR MECHANISTIC RATIONALE STRONG PRECLINICAL EVIDENCE Synaptic plasticity and LTP – both enhanced by NYX-458 – play key roles in learning and memory NMDAr dysregulation and dysfunction caused by neuronal loss (dopamine
Slide 39: NYX-458 exhibits robust, long-lasting effects on cognitive deficits in non-human primate model
NYX-458 exhibits robust, long-lasting effects on cognitive deficits in non-human primate model of Parkinson’s disease VARIABLE DELAYED RESPONSE (VDR) *MPTP is a neurotoxin employed to deplete dopamine-related neural cells -- similar to the way Parkinson’s disease does in humans Robust and rapid effe
Slide 40: Favorable tolerability and dose-proportional PK of NYX-458 observed in Phase 1 study
Favorable tolerability and dose-proportional PK of NYX-458 observed in 62-subject Phase 1 study SINGLE ASCENDING DOSE PLASMA PKMULTIPLE ASCENDING DOSE PLASMA PKCSF CONCENTRATION NYX-458 10 mg PO NYX-458 EXHIBITS FAVORABLE TOLERABILITY AND PK PROPERTIES: Predictable and dose-proportional PK Cleared f
Slide 41: Ongoing first-in-patient Phase 2 study of NYX-458 in Parkinson's MCI
Ongoing first-in-patient Phase 2 study of NYX-458 in Parkinson’s disease mild cognitive impairment (PD-MCI) N ≈ 135x SCREENINGTREATMENT (12 WEEKS)FOLLOW-UP PD (> 1 year) Cognitive Impairment - and - MoCA ≥ 17 (not severely impaired) PLACEBO NYX-458 10 mg NYX-458 30 mg NYX-458 100 mg Follow-up visit
Slide 42: Development summary of NYX-458 for cognitive impairment in Parkinson's disease
Development summary of NYX-458 for cognitive impairment in Parkinson’s disease xSTRONG PRECLINICAL EVIDENCE in numerous rodent models xROBUST REVERSAL OF COGNITIVE DEFICITS in non-human primate model of Parkinson’s disease xCOMPLETED PHASE 1 STUDY – favorable tolerability, PK, and CNS exposure demon
Slide 43: Supported by strong cash position while managing impacts of COVID-19 pandemic
Supported by strong cash position while responsibly managing impacts of COVID-19 pandemic Study NYX-783: Phase 2 PTSD Study Status & Impact of COVID-19 Pandemic • Data readout from Phase 2 exploratory study expected 4Q 2020 NYX-2925: Phase 2b fibromyalgia NYX-2925: Phase 2b painful DPN • Anticipate